NORTHBROOK, Ill., April 23,
2024 /PRNewswire/ -- Endevica Bio, a company
developing first-in-class peptide drug candidates, announced its
novel weight-loss treatment was successful in a recent diet-induced
obesity (DIO) rat study.
This latest research solidifies Endevica Bio's status as a world
leader in the scientific understanding of the central melanocortin
system. The company's proof-of-concept MC4R agonist compound A07D
leverages this biological pathway to induce weight loss in DIO
rats, both alone and in combination with GLP1s, while allowing the
retention of muscle mass.
Additionally, the treatment of A07D was found to provide durable
weight loss even after cessation of treatment – suggesting that
this approach avoids the problem of weight loss plateau and weight
rebound seen with use of GLP1s alone.
Results from the study support the idea that weight-regulating
effects such as those advanced by Endevica Bio to address
conditions such as involuntary cancer-related weight loss, can also
be harnessed to regulate weight in several disease areas in which
excess weight may be detrimental, including diabetes and
obesity.
Endevica Bio's goal is to advance this platform throughout 2024,
and the company's oral agonist portfolio for obesity-related
disorders is on track for Phase 1 studies in early 2025.
Meanwhile, Endevica Bio's most advanced drug candidate in the
weight modulation space, TCMCB07 (B07), will be entering Phase 2
studies this summer. ASCO and ESMO guidelines now specify body mass
management as a critical piece of cancer care, as increased mass
may confer survival benefit and an increase in quality of life in
cancer patients. For this reason, B07, which is intended to address
involuntary cancer-related mass loss, has the potential to become
part of the new standard of care in oncology.
Together, the findings on these sister molecules demonstrate how
Endevica Bio's peptide engineering resulted in several drug
candidates that may safely address multiple indications related to
metabolism, weight management, and oncology.
"We're thrilled with the research results showing our drug
candidate could potentially improve the lives of millions of people
who seek to lose weight," said Russell
Potterfield, CEO and Executive Chairman of Endevica Bio.
"The positive research findings lend additional credence to
Endevica Bio's vision of a new treatment paradigm that will both
help those suffering from involuntary cancer-related mass loss as
well as conditions in which weight loss is beneficial."
Dr. Daniel Marks, Chief Medical
Officer of Endevica Bio, agreed. "The elegance of these
peptide-based approaches is that we can engineer them to minimize
off-target actions," he said. "The potential of these drug
candidates is very exciting, and we look forward to exploring
additional ways in which these approaches can address some of the
most important diseases humanity faces."
About Endevica Bio
Endevica Bio creates first-in-class peptide drug candidates.
Endevica Bio's technology platform, protected by a family of
patents and pending applications, allows for the modification of
peptides to modulate activity of important drug targets behind the
blood-brain barrier. More information can be found at
www.endevicabio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/endevica-bio-drug-candidate-shows-success-in-weight-loss-in-new-study-302124298.html
SOURCE Endevica Bio